Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)

This study has been completed.
Information provided by (Responsible Party):
LEO Pharma Identifier:
First received: January 19, 2010
Last updated: February 18, 2014
Last verified: September 2010
This non-interventional, prospective, non-controlled study of Xamiol® Gel, a fixed combination of calcipotriol and betamethason dipropionate, shall investigate in daily routine the efficacy, tolerability and changes in quality-of-life parameters in patients with scalp psoriasis

Condition Intervention
Scalp Psoriasis
Drug: Xamiol® Gel

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Topical Treatment of Scalp Psoriasis With the Fixed Combination of Calcipotriol and Betamethason (Xamiol® Gel)

Resource links provided by NLM:

Further study details as provided by LEO Pharma:

Primary Outcome Measures:
  • Physician's Global Assessment of scalp psoriasis [ Time Frame: After approximately 4 weeks ]

Secondary Outcome Measures:
  • Patient's Quality of Life [ Time Frame: After approximately 4 weeks ]

Enrollment: 724
Study Start Date: January 2010
Study Completion Date: May 2010
Primary Completion Date: May 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Xamiol® Gel
    Once daily application for about 4 weeks

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients visiting their attending dermatologist in the primary care clinic

Inclusion Criteria:

  • Patients with scalp psoriasis if a treatment with Xamiol® gel is planned anyway

Exclusion Criteria:

  • Contraindications of Xamiol® Gel listed in the German package insert
  • Pretreatment with Xamiol® within the last 4 weeks
  • Systemic treatment of psoriasis
  • UV light therapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01052467

University Clinical Schleswig-Holstein, Campus Kiel
Kiel, Germany, 24105
Sponsors and Collaborators
LEO Pharma
Principal Investigator: Ulrich Mrowietz, MD University Clinic Schleswig-Holstein
  More Information

Responsible Party: LEO Pharma Identifier: NCT01052467     History of Changes
Other Study ID Numbers: Treatment with Xamiol® Gel
Study First Received: January 19, 2010
Last Updated: February 18, 2014

Additional relevant MeSH terms:
Skin Diseases, Papulosquamous
Skin Diseases
Dermatologic Agents processed this record on May 25, 2017